Spyre Deprioritizes SPY072 Monotherapy in Rheumatoid Arthritis After Mixed Phase II

Company: Spyre Therapeutics · Drug: SPY072 (Anti-TL1A) · Trial: SKYWAY-RA (Phase II) · Indication: Rheumatoid Arthritis · Date: August 25, 2026 Summary Spyre Therapeutics reported Week 12 results from the 143-patient Phase II SKYWAY-RA trial of the anti-TL1A antibody SPY072 in moderate-to-severe rheumatoid arthritis. The…